Related Experiment Video
Updated: Jul 14, 2026
06:38
Isolation of Adult Spinal Cord Nuclei for Massively Parallel Single-nucleus RNA Sequencing
Published on: October 12, 2018
Comparative Study of Single-Cell and Bulk RNA Sequencing Data from Metastatic Bone Marrow Neuroblastoma Samples
Sanja Aveic1, Alessandro Davini1, Sara Menegazzo1,2
1Pediatric Hematology, Oncology and Hematopoietic Cell & Gene Therapy Research Area, Pediatric Research Institute, Città della Speranza Foundation ETS, 35127 Padua, Italy.
Cells
|July 13, 2026
Summary
This study reveals neuroblastoma alters the bone marrow microenvironment, increasing regulatory T cells and "don't eat me" signals. Researchers identified new potential targets for neuroblastoma immunotherapy.
Area of Science:
- Oncology
- Immunology
- Genomics
Background:
- Neuroblastoma frequently metastasizes to bone marrow (BM).
- Understanding the tumor microenvironment is crucial for effective treatment.
Purpose of the Study:
- To analyze the cellular heterogeneity of metastatic neuroblastoma in the bone marrow.
- To identify interactions between neuroblastoma cells and the BM microenvironment.
- To discover potential therapeutic targets for neuroblastoma.
Main Methods:
- Single-cell RNA sequencing (scRNA-seq) of metastatic BM samples.
- Comparison with bulk RNA sequencing data.
- Computational analysis of cell-cell communication networks.
- Validation of candidate tumor antigens.
Main Results:
- Enrichment of regulatory T cells and activation of "don't eat me" signals (CD24, CD47, CD200) in the BM.
- Identified neuroblastoma-myeloid cell communication via amyloid precursor protein (APP) and midkine (MK) signaling.
- Discovered distinct neuroblastoma cell states (adrenergic, transitory) and ten sub-clusters.
- Validated CNTFR and CHRNA3 as selective neuroblastoma antigens.
Conclusions:
- Neuroblastoma significantly modulates the bone marrow ecosystem.
- These findings impact immunotherapy strategies by highlighting immune evasion mechanisms.
- Single-cell analysis reveals novel antigens for targeted therapies.
